MedTrace Logo

Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson's Disease

NCT03720418 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-05-03

No results posted yet for this study

Summary

This study consists of two parts. Part A will evaluate the safety and tolerability of multiple doses of OXB-102 (AXO-Lenti-PD) in participants with Parkinson's disease. Part B will assess the safety and efficacy of the selected dose of OXB-102 in participants with Parkinson's disease.

Conditions

  • Parkinson Disease

Interventions

DRUG

OXB-102

Neurosurgical delivery of OXB-102 (gene therapy) to the putamen

OTHER

Imitation Surgical Procedure (ISP)

Participants randomized to the control group in Part B will receive an ISP

Sponsors & Collaborators

  • Sio Gene Therapies

    lead INDUSTRY

Principal Investigators

  • Erika De Boever, DDS, PhD · Sio Gene Therapies

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-17
Primary Completion
2022-04-12
Completion
2022-04-12

Countries

  • France
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03720418 on ClinicalTrials.gov